title: Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers.
abstract: OBJECTIVE
  Most studies have shown that prognosis of heart failure with preserved systolic function is as poor as that of heart failure with depressed systolic function, although these results may be biased by the fact that these types of heart failure have different characteristics (age, comorbidity, treatment), which can influence prognosis. Our aim was to determine whether short-term morbidity and mortality differed in these 2 subgroups of heart failure patients when they were comparable in terms of age, associated comorbidity, and therapy.
  
  
  METHODS
  We analyzed 2 groups of patients aged >70 years who were candidates to receive beta blockers (preserved systolic function, 245; depressed systolic function, 374), consecutively discharged from 53 participating Spanish hospitals with a diagnosis of heart failure, and compared cardiovascular morbidity and mortality 3 months after discharge.
  
  
  RESULTS
  Mean age was similar (77.5±4.8 vs 78.2±5.5 years). Left ventricular ejection fraction was 56.2%±8.1% vs 33%±6.9% (P<.001). The combined event rate (death, hospitalization for heart failure, acute coronary syndrome, or stroke) at 3 months after discharge was lower in patients with heart failure and preserved systolic function (13.4% vs 20.6%; P=.026). Depressed systolic function was an independent predictor of greater incidence of events (odds ratio=1.732; P=.048).
  
  
  CONCLUSIONS
  In patients of similar age and receiving similar treatment, short-term prognosis is better in patients with heart failure and preserved systolic function than in those with depressed systolic function.
authors: Servicio de Cardiología, Hospital Reina Sofía, Córdoba, España. manuelp.anguita.sspa@juntadeandalucia.es
authors: Manuel
authors: M
authors: Anguita
authors: Juan C
authors: JC
authors: Castillo
authors: Martín
authors: M
authors: Ruiz
authors: Francisco
authors: F
authors: Castillo
authors: Manuel
authors: M
authors: Jiménez-Navarro
authors: Marisa
authors: M
authors: Crespo
authors: Luis
authors: L
authors: Alonso-Pulpón
authors: Eduardo
authors: E
authors: de Teresa
authors: Alfonso
authors: A
authors: Castro-Beiras
authors: Eulalia
authors: E
authors: Roig
authors: Remei
authors: R
authors: Artigas
authors: Antonio
authors: A
authors: Zapata
authors: Ignacio López
authors: IL
authors: de Ullibarri
authors: Javier
authors: J
authors: Muñiz
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000502:physiology; D002318:Cardiovascular Diseases / Q000401:mortality / Q000628:therapy; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D054143:Heart Failure, Systolic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D016015:Logistic Models; D008297:Male; D011379:Prognosis; D013030:Spain / Q000453:epidemiology; D013318:Stroke Volume / Q000502:physiology; D013599:Systole / Q000502:physiology*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists